Common Contracts
7 similar Securities Purchase Agreement contracts by Orgenesis Inc., Bellerophon Therapeutics, Inc., Caladrius Biosciences, Inc., others
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 13th, 2023 • Orgenesis Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of August 31, 2023 (the “Effective Date”), by and among Orgenesis Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 1st, 2023 • Orgenesis Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of August 31, 2023 (the “Effective Date”), by and among Orgenesis Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 5th, 2022 • Orgenesis Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of March 30, 2022 (the “Effective Date”), by and among Orgenesis Inc., a Nevada corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
CODEXIS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 20th, 2019 • Codexis, Inc. • Industrial organic chemicals • California
This Securities Purchase Agreement (“Agreement”) is made as of June 20, 2019 (the “Effective Date”), by and among Codexis, Inc., a Delaware corporation (the “Company”), and each entity, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement ("Agreement") is made as of September 26, 2017 (the "Effective Date"), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"),...Securities Purchase Agreement • October 4th, 2017 • Puissance Cross-Border Opportunities III LLC • New York
BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement ("Agreement") is made as of September 26, 2017 (the "Effective Date"), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the "Schedule of Purchasers"). Such persons and entities are hereinafter collectively referred to herein as "Purchasers" and each individually as a "Purchaser." AGREEMENT In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and each Purchaser (severally and not jointly) hereby agree as follows: SECTION 1. AUTHORIZATION OF SALE OF SECURITIES. The Company has authorized the sale and issuance of 19,449,834 shares of its Common Stock, par value $0.01 per share (the "Common Stoc
BELLEROPHON THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 27th, 2017 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of September 26, 2017 (the “Effective Date”), by and among Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
CALADRIUS BIOSCIENCES, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 5th, 2016 • Caladrius Biosciences, Inc. • Services-misc health & allied services, nec • New York
This Securities Purchase Agreement (“Agreement”) is made as of March 10, 2016 (the “Effective Date”), by and among Caladrius Biosciences, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser.”
